HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

[A. L. Pendley]

I'm interested in the HKI 272 Naratinib + Xeloda + Herceptin trial. I am currently in the Arry 380 trial which has a similar goal - to treat mets in the brain as well as in the rest of the system. I've been in the Arry 380 study now for 5 weeks and get my 6-week scans next week to see if I'm still included in the study (if I'm stable or improved). I want to stay on it, but if I can't, I hope Naratinib becomes another option. I'll be watching what others say on both of these trials! Ann